Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on trial using depot testosterone undecanoate.
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 02 Jul 2015 Planned End Date changed from 15 Oct 2014 to 15 Jan 2015 as reported by United Kingdom Clinical Research Network record.
- 02 Jul 2015 Status changed from recruiting to suspended as reported by United Kingdom Clinical Research Network record.
- 08 Jan 2015 Accrual to date is 61% according to United Kingdom Clinical Research Network record.